Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan

MeSH terms

• Antibodies, Monoclonal / adverse effects*
• Antibodies, Monoclonal / therapeutic use
• Antibodies, Monoclonal, Humanized
• Antineoplastic Combined Chemotherapy Protocols / adverse effects*
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use
• Benzamides
• Blast Crisis / diagnosis*
• Blast Crisis / drug therapy
• Blast Crisis / genetics
• Camptothecin / adverse effects
• Camptothecin / analogs & derivatives*
• Camptothecin / therapeutic use
• Cetuximab
• Chemotherapy, Adjuvant / adverse effects
• Colorectal Neoplasms / diagnosis
• Colorectal Neoplasms / drug therapy*
• Colorectal Neoplasms / secondary
• Diagnosis, Differential
• Disease Progression
• Fusion Proteins, bcr-abl / genetics
• Humans
• Imatinib Mesylate
• Irinotecan
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis*
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
• Leukocyte Count
• Male
• Middle Aged
• Neoplasm Staging
• Neoplasms, Second Primary / diagnosis*
• Neoplasms, Second Primary / drug therapy
• Neoplasms, Second Primary / genetics
• Piperazines / therapeutic use
• Pyrimidines / therapeutic use
• Remission Induction
• Sensitivity and Specificity
• Tomography, X-Ray Computed
• Treatment Outcome